Agios Pharma Director Sells $8.2k in Stock via 10b5-1 Plan
AGIOS PHARMACEUTICALS, INC.
Subscribe to track AGIO
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Agios Pharma Director Sells $8.2k in Stock via 10b5-1 Plan
Company: AGIOS PHARMACEUTICALS, INC. (AGIO) Form: 4 | Filed: 2025-10-10 Significance: Low
Insider: Scadden David Title: null | Relationship: Director
Transaction: • Type: Sell (following option exercise) • Shares: 200 • Price: $41.00 • Value: $8,200 • Owned After: 17,603
Key Insight: This was a small, pre-planned sale executed under a Rule 10b5-1 trading plan, which significantly reduces its informational value. The transaction involved exercising options and immediately selling the acquired shares.
Market Context: Pre-scheduled trades like this are common for insiders to systematically liquidate portions of their holdings for personal financial planning and are generally not indicative of a change in their outlook on the company.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: AGIOS PHARMACEUTICALS, INC. (AGIO)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A director at Agios Pharmaceuticals conducted a small, pre-planned 'exercise and sell' transaction valued at $8,200 under a Rule 10b5-1 plan. This type of trade is typically for personal liquidity and is not considered a significant indicator of the insider's sentiment.
- Market Impact: Neutral. The small size of the transaction and its execution under a pre-arranged trading plan mean it is unlikely to have any material impact on the stock price or market sentiment.
Company Information
| Field | Value |
|---|---|
| Company | AGIOS PHARMACEUTICALS, INC. |
| Ticker Symbol | AGIO |
| CIK | 0001439222 |
| Industry | PHARMACEUTICAL PREPARATIONS [2834] |
Insider Information
| Field | Value |
|---|---|
| Name | Scadden David |
| CIK | 0001707715 |
| Title/Position | null |
| Relationship | Director |
Transaction Details
This filing reports two related non-derivative transactions: an option exercise followed by a sale.
| Field | Exercise (Code M) | Sale (Code S) |
|---|---|---|
| Form Type | 4 | 4 |
| Transaction Date | 2025-10-08 | 2025-10-08 |
| Transaction Code | M (Exercise of option) | S (Open market sale) |
| Security Type | Common Stock | Common Stock |
| Shares Involved | 200 | 200 |
| Price Per Share | $18.09 | $41.00 |
| Total Value | $3,618 | $8,200 |
| Shares Owned After | 17,803 | 17,603 |
| Ownership Type | Direct | Direct |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The sale was executed under a Rule 10b5-1 plan, indicating it was scheduled in advance and not based on any immediate material non-public information. The value of the sale ($8,200) is immaterial for both the insider and the company's market capitalization.
Volume & Sentiment
- Expected Volume Impact: Negligible. A 200-share trade will not noticeably affect daily trading volume.
- Sentiment Indicator: Neutral. Automated sales via 10b5-1 plans are not considered bearish signals. They are routine financial planning activities.
Investment Insights
Positive Market Indicators
- The insider still directly owns 17,603 shares of common stock and 27,107 stock options after the transaction, maintaining a significant vested interest in the company's success.
Risk Factors
- No new risk factors are indicated by this specific filing. The transaction appears to be routine.
Key Takeaways
- Pre-Planned Sale: The transaction was made pursuant to a Rule 10b5-1 trading plan, stripping it of most predictive value.
- Cashless Exercise Pattern: This is a classic 'exercise and sell' transaction, where an insider exercises stock options and immediately sells the resulting shares, often to cover the exercise cost and taxes, while realizing a small profit.
- Immaterial Value: The total sale value of $8,200 is too small to be considered a significant move by a corporate director.
Contextual Analysis
Timing Significance
- The transaction date does not coincide with any major company announcements, further suggesting it is a routine, pre-scheduled event rather than a reaction to recent developments.
Transaction Context
- As noted in Footnote F1, the transaction was part of a 10b5-1 plan. These plans allow insiders to set up a trading schedule in advance to avoid accusations of trading on inside information. The exercised options were granted in June 2022 and became fully vested after one year.
Company Context
- Analysis of this filing should be paired with a broader look at Agios Pharmaceuticals' recent performance, clinical trial pipeline, and upcoming earnings reports to form a complete investment picture. This isolated transaction provides little insight on its own.
Risk Assessment
Risk Level: Low
Risk Factors
- Interpretation Risk: An uninformed investor might misinterpret this sale as a bearish signal without understanding the context of the 10b5-1 plan.
- Transaction Size: The transaction is not large enough to pose any market risk.
Market Considerations
- The primary market consideration is to correctly identify this as a non-informational trade and not assign any undue weight to it when evaluating the stock.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-10 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.